TrialAnnals of oncology : official journal of the European Society for Medical Oncology2026

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo).

A W Hahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.